Inhibitors of tyrosine kinases and uses thereof

Abstract

Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-mediated diseases or conditions or tyrosine kinase-dependent diseases or conditions are provided.

1 .- 26 . (canceled) 
     
     
         27 . A method for treating a lymphoma in a subject comprising administering to a subject in need thereof an inhibitor of Bruton's tyrosine kinase (Btk). 
     
     
         28 . The method of  claim 27 , wherein the lymphoma is a Hodgkin's lymphoma. 
     
     
         29 . The method of  claim 27 , wherein the lymphoma is a non-Hodgkin's lymphoma. 
     
     
         30 . The method of  claim 27 , wherein the lymphoma is selected from nodal marginal zone B cell lymphoma, extranodal marginal zone B cell lymphoma, splenic marginal zone B cell lymphoma, diffuse large B cell lymphoma, follicular lymphoma, Waldenstrom macroglobulinemia, or Mantle Cell Lymphoma. 
     
     
         31 . A method of treating a chronic lymphocytic leukemia in a subject comprising administering to a subject in need thereof an inhibitor of Bruton's tyrosine kinase (Btk). 
     
     
         32 . A method of treating an acute lymphoblastic leukemia in a subject comprising administering to a subject in need thereof an inhibitor of Bruton's tyrosine kinase (Btk). 
     
     
         33 . A method of treating a multiple myeloma in a subject comprising administering to a subject in need thereof an inhibitor of Bruton's tyrosine kinase (Btk). 
     
     
         34 . A method of treating a leukemia in a subject comprising administering to a subject in need thereof an inhibitor of Bruton's tyrosine kinase (Btk), wherein the leukemia is selected from hairy cell leukemia, chronic and acute myelogenous leukemia, B-cell prolymphocytic leukemia, or burkitt leukemia. 
     
     
         35 . The method of any of  claims 27  and  31 - 34 , wherein the inhibitor of Bruton's tyrosine kinase is a reversible inhibitor of Btk. 
     
     
         36 . A method for treating a disorder characterized by the presence or development of one or more solid tumors comprising administering to an individual in need thereof an inhibitor of Bruton's tyrosine kinase (Btk). 
     
     
         37 . The method of  claim 36 , wherein the solid tumor is a lymphoma. 
     
     
         38 . The method of  claim 36 , wherein the inhibitor of Bruton's tyrosine kinase is a reversible inhibitor of Btk.